Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Citrate vs Sevelamer for Hyperphosphatemia in Hemodialysis CKD (China, Phase 3)
CTR20191035Phase 3Completed
- Sponsor
- Pao Ling Biotechnology
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric citrate in hyperphosphatemia, chronic kidney disease (CKD), end-stage kidney disease (ESKD), sponsored by Pao Ling Biotechnology. Started May 2019; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20191035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191035.